ISRCTN73221288已完成未知
Pharmacological treatment of depression
Erasmus Medical Center (The Netherlands)0 个研究点目标入组 138 人开始时间: 2006年4月28日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 138
研究概览
简要总结
2017 results in: https://www.ncbi.nlm.nih.gov/pubmed/28478653
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •For inclusion in the trial, patients must fulfill all of the following criteria:
- •1. Age 18-65
- •2. Major depressive disorder, single or recurrent episode (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition [DSM-IV])
- •3. Hamilton Rating Scale for Depression (HRSD) (17 item) >/= 14
- •4. Written informed consent
排除标准
- •Any of the following is regarded as a criterion for exclusion from the trial:
- •1. Patients who are incapable of understanding the information and of giving informed consent. Also, patients who are unable to read or write
- •2. Major depression with psychotic features (separate study)
- •3. Bipolar I or II disorder
- •4. Schizophrenia or other primary psychotic disorder
- •5. Treatment of current episode with adequate trial of Imipramine or Venlafaxine
- •6. Drug/alcohol dependence in the last 3 months
- •7. Mental retardation (IQ <80)
- •8. Women: pregnancy or possibility for pregnancy and no adequate contraceptive measures. Breastfeeding.
- •9. Serious medical illness affecting central nervous system (CNS) e.g. M. Parkinson, systemic lupus erythematosus (SLE), brain tumor, cerebrovascular accident (CVA)
- •10. Relevant medical illness as contra-indications for the use of study medication (Venlafaxine and Imipramine), such as recent myocardial infarction and severe liver or kidney failure
- •11. Medication affecting CNS e.g. antidepressants and/or antipsychotics other than study medication, steroids (prednison), mood stabilisers, benzodiazepines (if not being tapered): >3 mg lorazepam (or equivalent)
- •12. Direct electroconvulsive therapy (ECT) indication (e.g. very severely suicidal or refusal of food and drinking resulting in life threatening situation)
- •13. Contra-indications for Lithium (Moleman, 1998):
- •13.1. Kidney failure
- •13.2. Acute myocardial infarction
- •13.3. Myasthenia gravis
- •13.4. Breastfeeding
研究者
相似试验
已完成
不适用
Pharmacological treatment of Depression: Phase II Lithium additioDepressionISRCTN75768415Erasmus Medical Center (The Netherlands)69
已完成
不适用
The predictors of response to antidepressant treatment in patients with resistant depression-an integrative approachISRCTN25983493Ministry of Health (Czech Republic) - Internal Grant Agency40
已完成
2 期
Pilot randomised controlled trial of augmented depression therapyDepressionISRCTN85278228niversity of Exeter82
已完成
不适用
The investigation of treatment for major depression compared monotherapy of mirtazapine, sertraline or duloxetine with combination therapy of mirtazapine and sertraline, or mirtazapine and duloxetineMajor depressionJPRN-UMIN000004567Kenichi Osada500
已完成
不适用
Behavioural activation therapy for depression after strokeISRCTN12715175niversity of Nottingham (UK)48